DOCSLIB.ORG

Boards' Fodder

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Boards' Fodder boards’ fodder Porphyrias Sharon E. Jacob, MD, and Hari Nadiminti, MD. (Updated July 2015*) 4,5-Dioxovalerate + L-Alanine PORPHYRIN-HEME BIOSYNTHETIC PATHWAY Figure based on Fitzpatrick, 1999, page 1768 Glycine + Succinyl CoA Aminotransferase I. ALA-S II. ALA-D III. PBG-D HYDROXYMETHYLBILANE ALA PBG ALADD AIP CEP IV. UROIIS UROGEN III UROGEN I URO I PCT/HEP V. URO-D V. URO-D 5-Carboxyl porphyrin COPROGEN I COPRO I HEME V. URO-D COPR-O R R E V. URO-D F Dehydroisocoprogen COPRO III COPROGEN III . P III HCP VI. COPR-O P V E VII. PROT-O VI. COPR-O ISOCOPRO PROTO IX PROTOGEN IX HARDEROGEN MITOCHONDRIA KEY: KEY: MNEUMONICSMNEUMONICS: and TIPS: Roman numerals represent chronological order, starting with 4 mitochodrial enzymes: “ALAS, FERRous Roman numerals represent chronological order, starting with ALA-s 4 mitochodrial enzymes: “ ALAS, FERRous ALA-s (rate limiting step enzyme) (rate limiting step enzyme) OXIDizes” (ALAS, FerrOXIDochelatase,izes” [ALAS the, Fer Oxidrochelataseases) & the Oxidases] Diseases in teal, enzymes in bold. Diseases in dark purple, enzymes in bold. Light purple indicates mitochondriAIP a& ALADD: AbsentAIP skin & AfindingsLADD: Absent skin findings Light teal indicates mitochondria HCP, AIP, and VIP: HAVHCeP ,acute AIP, and attacks VIP :ofH ALA,AVe PBGacute attacks of ALA, PBG “No pee pee in EPP” (no porphyrins in the urine in EPP) “No pee pee in EPP” [no porphyrins in the ABBREVIATIONS: urine in EPP ALA-S:aminolevulinic acid synthase HCP:hepatic coproporphyria ALADD:ALA dehydratase deficiency HEP:hepaticABBREVIATIONS: erythropoietic porphyria AIP:acute intermittent porphyria PBG-D:porphobilinogen deaminase ALA-S: aminolevulinic acid synthase HEP: hepatic erythropoietic porphyria ALA-D:ALA dehydratase PCT:porp hyria cutanea tarda PROT-O:protoporphyrin; CEP:congenital erythropoieticALADD: porpALAh dehydrataseyria deficiency PBG-D: porphobilinogen deaminase PROTOGEN: protoporphyrinogen COPR-O:corproporphrin oxidase AIP: acute intermittentUR O:porphyria uroporphyrin PCT: porphyria cutanea tarda COPROGEN: coproporphyinogen UROGEN: uroporphyrinogen EPP:erythropoieticALA-D: protoporp ALAhyria dehydrataseURO-D:urogen decarboxylasePROT-O: protoporphyrin FERR:ferrochelatase UROIIIS:urogen synthase III HARDEROGEN: harderoporpCEP: congenitalhyinogen erythropoieticVP:variegate porphyria porphyria PROTOGEN: protoporphyrinogen COPR-O: corproporphrin oxidase URO: uroporphyrin COPROGEN: coproporphyinogen UROGEN: uroporphyrinogen EPP: erythropoietic protoporphyria URO-D: urogen decarboxylase FERR: ferrochelatase UROIIIS: urogen synthase III HARDEROGEN: harderoporphyinogen VP: variegate porphyria HCP: hepatic coproporphyria irectionsin D Residency p. 1 • Spring 2005 boards’ fodder Porphyrias Sharon E. Jacob, MD and Hari Nadiminti, MD. (Updated July 2015*) ENZYME DISEASE DEF INHERITANCE INHERITANCE CLINICAL FEATURES TREATMENT RBC URINE STOOL FLUORO I ALAS Proto ALA/ Copro ALA II ALA-D ALADD AR Rare (< 10 reported cases); sxs can mimic Acute attacks: AIP & are highly variable; failure to thrive Hematin in infant & polyneuropathy in a 63 y/o; r/o exposure to styrene (inhibitor of ALAD) Tyrosinemia Can mimic ALADD, b/c pts with hereditary Diet to minimize the tyrosinemia accumulate succinylacetone phenylalanine-tyrosine (inhibitor of ALAD) III PBG-D AIP AD Incidence: 5 / 100,000; women > men Glucose load, PBG ALA, PBG N/ (2:1); onset: 18 -40 y/o; sx sequence: abd colic Hematin/cimetidine deami- Watson- ALA/ → psychiatric sxs, ie hysteria → peripheral Pain: narcotics; nase Scharwtz PBG in neuropathy; NO SKIN FINDINGS; SIADH Liver transplant – test attacks → hyponatremia; urine discoloration; risk cure (1 case report) Hepatic CA IV UROIIIS CEP AR Rare (<200 reported cases); onset: Sun avoidance, Uro> Uro> Copro> Teeth (Gunther’s) infancy: marked photosensitivity (vesiculo- Splenectomy, Copro Copro Uro Urine, bullous-scaring), increased fragility and BMT, ß-carotene, RBC ulcers lead to scarring; “werewolf-facies”; transfusions, hypertrichosis, erythrodontia; hemolytic alphatocopherol anemia; splenomegaly; port wine urine; corneal scarring → blindness; acro- osteolysis; contractures V URO-D PCT AD Most common porphyria; onset: middle EtOH elimination, N Uro> copro Isocopro Urine Types: age; Associated with Hepatitis C; sun protection, I: Sporadic moderate photosensitivity, fragility of sun- Phlebotomy to Hb<10, II: Familial exposed skin after trauma → erosions & antimalarials bullae → scars, hyper/hypopigmentation, milia; hypertrichosis; scarring alopecia; photo-oncholysis; sclerodermoid plaques; dystrophic calcifications; serum iron normal; DM 25%; liver iron overload; mutation: HFE C2a2 HEP AR Homozygous form of PCT; URO-D <10%; Strict sun avoidance, Proto Uro Isocopro Teeth onset: infancy; extreme photosensitivity; Phlebotomy similar sxs as PCT (earlier onset) ineffective VI COPR-O HCP AD Incidence: 1-4 / 1,000,000; onset; 18-40; Glucose load, Hematin N Copro Copro similar sxs to AIP, but less severe; 30% Pain: narcotics have skin findings: Hematinphotosensitivity → blistering, scarring; during attacks urine pink/red; mutation in CPOX Hardero- Rare form of HCP; onset: infancy; sxs porphyria similar to HCP, with jaundice and anemia ECP Rare (3 reported cases); mild skin Copro Copro photosensitivity VII PROT-O VP AD Common in South Africans; 15-30 Glucose load, N Copro> Proto> RBC y/o; clinically similar to AIP (abd colic, Hematin Uro* Copro paralysis, psychosis) + PCT skin findings (photosensitivity); mutation PPOX; 624-626 nm band VIII FERR EPP AD (AR) Photosensitivity beginning in first decade; Sun avoidance, Proto N Proto RR burning and tingling (non-pruritic); ß-carotene, edematous plaques- purpura, waxy scars; Cholestyramine pox-like scarring on nose & cheeks; circumoral linear scars; weather-beaten skin; cholelithiasis; hepatic failure Buzz words-Diagnostic hints: Blistering associated with PCT, VP, CEP, HCP, HEP. If blistering with normal porphyrin labs, screen known associations with Pseudoprophyria (HD, tanning booths, drug [NSAID, abx, diuretics]). Burning, erythema, without blisters, is seen in EPP or XLDPP. No skin findings, AIP or ALADD. Red teeth: CEP or HEP.. *Reviewed and updated July 2015: Alina Goldenberg, MD, Elise Herro, MD, Emily deGolian, MD & Sharon Jacob, MD. irectionsin www.aad.org/DIR Spring 2005 • p. 2 D Residency.
Load more

Recommended publications
  • Phlebotomy As an Efficient Long-Term Treatment of Congenital
    Letters to the Editor after chronic gastrointestinal bleeding that resulted in Phlebotomy as an efficient long-term treatment of iron deficiency.4 They treated her with an iron chelator, congenital erythropoietic porphyria resulting in correction of the hemolysis, decreased por- phyrin levels and improved quality of life with reduced Congenital erythropoietic porphyria (CEP, MIM photosensitivity. We recently identified three CEP sib- 263700) is a rare autosomal recessive disease caused by lings with phenotypes ranging from moderate to asymp- impaired activity of uroporphyrinogen III synthase tomatic which were modulated by iron availability, high- (UROS), the fourth enzyme of the heme biosynthetic lighting the importance of iron metabolism in the disease. 1 pathway. Accumulation of porphyrins in red blood cells, Based on these data, we prospectively treated a CEP mainly uroporphyrinogen I (URO I) and copropor- patient with phlebotomies to investigate the feasibility, phyrinogen I (COPRO I), leads to ineffective erythro- safety and efficacy of this treatment. We observed dis- poiesis and chronic hemolysis. Porphyrin deposition in continuation of hemolysis and a marked decrease in plas- the skin is responsible for severe photosensitivity result- ma and urine porphyrins. The patient reported a major ing in bullous lesions and progressive photomutilation. improvement in photosensitivity. Finally, erythroid cul- Treatment options are scarce, relying mainly on support- tures were performed, demonstrating the role of iron in ive measures and, for severe cases, on bone marrow the rate of porphyrin production. transplantation (BMT). Increased activation of the heme The study was conducted in accordance with the biosynthetic pathway by gain-of-function mutations in World Medical Association Declaration of Helsinki ethi- ALAS2, the first and rate-limiting enzyme, results in a 2 cal principles for medical research involving human sub- more severe phenotype.
    [Show full text]
  • Module 01: Classification of Porphyria
    MODULE 01 Classification of Porphyria Do not reprint, reproduce, modify or distribute this material without the prior written permission of Alnylam Pharmaceuticals. © 20120199 Alnylam PharmaceuticalsPharmaceuticals,, Inc.Inc. All rights reserved. -USA-00001-092018 1 Porphyria—A Rare Disease of Clinical Consequence • Porphyria is a group of at least 8 metabolic disorders1,2 – Each subtype of porphyria involves a genetic defect in a heme biosynthesis pathway enzyme1,2 – The subtypes of porphyria are associated with distinct signs and symptoms in patient populations that can differ by gender and age1,3 • Prevalence of some subtypes of porphyria may be higher than generally assumed3 Estimated Prevalence of Most Common Subtypes of Porphyria1,4 Estimated Prevalence Based on European Subtype of Porphyria and US Data Porphyria cutanea tarda (PCT) 1/10,000 (EU)1 0.118-1/20,000 (EU)1,4 Acute intermittent porphyria (AIP) 5/100,000 (US)1 Erythropoietic protoporphyria (EPP) 1/50,000-75,000 (EU)1 1. Ramanujam V-MS, Anderson KE. Curr Protoc Hum Genet. 2015;86:17.20.1-17.20.26. 2. Puy H et al. Lancet. 2010;375:924-937. 3. Bissell DM et al. N Engl J Med. 2017;377:862-872. 4. Elder G et al. J Inherit Metab Dis. 2013;36:848-857. Do not reprint, reproduce, modify or distribute this material without the prior written permission of Alnylam Pharmaceuticals. © 2019 Alnylam Pharmaceuticals, Inc. All rights reserved. -USA-00001-092018 2 Classification of Porphyria Porphyria can be classified in 2 major ways1,2: 1 According to major physiological sites: liver or 2 According to major clinical manifestations1,2 bone marrow1,2 • Heme precursors originate in either the liver or Acute Versus Photocutaneous Porphyria bone marrow, which are the tissues most • Major clinical manifestations are either neurovisceral active in heme biosynthesis1,2 symptoms (eg, severe, diffuse abdominal pain) associated with acute exacerbations or cutaneous lesions resulting from phototoxicity1,2 • Acute hepatic porphyria may be somewhat of a misnomer since the clinical features may be prolonged and chronic3 1.
    [Show full text]
  • Successful Therapeutic Effect in a Mouse Model of Erythropoietic Protoporphyria by Partial Genetic Correction and fluorescence-Based Selection of Hematopoietic Cells
    Gene Therapy (2001) 8, 618–626 2001 Nature Publishing Group All rights reserved 0969-7128/01 $15.00 www.nature.com/gt RESEARCH ARTICLE Successful therapeutic effect in a mouse model of erythropoietic protoporphyria by partial genetic correction and fluorescence-based selection of hematopoietic cells A Fontanellas1,2, M Mendez1, F Mazurier1, M Cario-Andre´1, S Navarro2, C Ged1, L Taine1,3, FGe´ronimi1, E Richard1, F Moreau-Gaudry1, R Enriquez de Salamanca2 and H de Verneuil1 1Laboratoire de Pathologie Mole´culaire et The´rapie Ge´nique, Universite´ Victor Segalen Bordeaux 2, France; 2Centro de Investigacio´n, Hospital 12 de Octubre, Madrid, Spain; and 3Laboratoire de Ge´ne´tique, CHU Pellegrin, Bordeaux, France Erythropoietic protoporphyria is characterized clinically by transplantation, the number of fluorescent erythrocytes skin photosensitivity and biochemically by a ferrochelatase decreased from 61% (EPP mice) to 19% for EPP mice deficiency resulting in an excessive accumulation of photore- engrafted with low fluorescent selected BM cells. Absence active protoporphyrin in erythrocytes, plasma and other of skin photosensitivity was observed in mice with less than organs. The availability of the Fechm1Pas/Fechm1Pas murine 20% of fluorescent RBC. A partial phenotypic correction was model allowed us to test a gene therapy protocol to correct found for animals with 20 to 40% of fluorescent RBC. In con- the porphyric phenotype. Gene therapy was performed by ex clusion, a partial correction of bone marrow cells is sufficient vivo transfer of human ferrochelatase cDNA with a retroviral to reverse the porphyric phenotype and restore normal hem- vector to deficient hematopoietic cells, followed by re-injec- atopoiesis.
    [Show full text]
  • Acute Intermittent Porphyria: an Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators
    International Journal of Molecular Sciences Review Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators Helene J. Bustad 1 , Juha P. Kallio 1 , Marta Vorland 2, Valeria Fiorentino 3 , Sverre Sandberg 2,4, Caroline Schmitt 3,5, Aasne K. Aarsand 2,4,* and Aurora Martinez 1,* 1 Department of Biomedicine, University of Bergen, 5020 Bergen, Norway; [email protected] (H.J.B.); [email protected] (J.P.K.) 2 Norwegian Porphyria Centre (NAPOS), Department for Medical Biochemistry and Pharmacology, Haukeland University Hospital, 5021 Bergen, Norway; [email protected] (M.V.); [email protected] (S.S.) 3 INSERM U1149, Center for Research on Inflammation (CRI), Université de Paris, 75018 Paris, France; valeria.fi[email protected] (V.F.); [email protected] (C.S.) 4 Norwegian Organization for Quality Improvement of Laboratory Examinations (Noklus), Haraldsplass Deaconess Hospital, 5009 Bergen, Norway 5 Assistance Publique Hôpitaux de Paris (AP-HP), Centre Français des Porphyries, Hôpital Louis Mourier, 92700 Colombes, France * Correspondence: [email protected] (A.K.A.); [email protected] (A.M.) Abstract: Acute intermittent porphyria (AIP) is an autosomal dominant inherited disease with low clinical penetrance, caused by mutations in the hydroxymethylbilane synthase (HMBS) gene, which encodes the third enzyme in the haem biosynthesis pathway. In susceptible HMBS mutation carriers, triggering factors such as hormonal changes and commonly used drugs induce an overproduction Citation: Bustad, H.J.; Kallio, J.P.; and accumulation of toxic haem precursors in the liver. Clinically, this presents as acute attacks Vorland, M.; Fiorentino, V.; Sandberg, characterised by severe abdominal pain and a wide array of neurological and psychiatric symptoms, S.; Schmitt, C.; Aarsand, A.K.; and, in the long-term setting, the development of primary liver cancer, hypertension and kidney Martinez, A.
    [Show full text]
  • Biochemical Differentiation of the Porphyrias
    Clinical Biochemistry, Vol. 32, No. 8, 609–619, 1999 Copyright © 1999 The Canadian Society of Clinical Chemists Printed in the USA. All rights reserved 0009-9120/99/$–see front matter PII S0009-9120(99)00067-3 Biochemical Differentiation of the Porphyrias J. THOMAS HINDMARSH,1,2 LINDA OLIVERAS,1 and DONALD C. GREENWAY1,2 1Division of Biochemistry, The Ottawa Hospital, and the 2Department of Pathology and Laboratory Medicine, University of Ottawa, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada Objectives: To differentiate the porphyrias by clinical and biochem- vals for urine, fecal, and blood porphyrins and their ical methods. precursors in the various porphyrias and in normal Design and methods: We describe levels of blood, urine, and fecal porphyrins and their precursors in the porphyrias and present an subjects and have devised an algorithm for investi- algorithm for their biochemical differentiation. Diagnoses were es- gation of these diseases. Except for Porphyria Cuta- tablished using clinical and biochemical data. Porphyrin analyses nea Tarda (PCT), our numbers of patients in each were performed by high performance liquid chromatography. category of porphyria are small and therefore our Results and conclusions: Plasma and urine porphyrin patterns reference ranges for these should be considered were useful for diagnosis of porphyria cutanea tarda, but not the acute porphyrias. Erythropoietic protoporphyria was confirmed by approximate. erythrocyte protoporphyrin assay and erythrocyte fluorescence. Acute intermittent porphyria was diagnosed by increases in urine Materials and methods delta-aminolevulinic acid and porphobilinogen and confirmed by reduced erythrocyte porphobilinogen deaminase activity and nor- REAGENTS AND CHEMICALS mal or near-normal stool porphyrins.
    [Show full text]
  • Four Novel Mutations in the Ferrochelatase Gene Among Erythropoietic Protoporphyria Patients
    Four Novel Mutations in the Ferrochelatase Gene among Erythropoietic Protoporphyria Patients Matti H enriksson,* Kaisa Timonen,-j" Pertti Mustajoki,* Hannele Pihlaja,* Raimo Tenhunen ,:I: Leena Peltonen,§ and Raili Kauppinen * Departments of ' Medicin c, 'I' Dermatology, and :f:C lin ical Chemistry, Uni versity of Hclsin !ci; and §Depa rtrn cnt of I-IU111:111 Molccular Genetics , National Public Health In stitute, Helsinki, Finland A novel mutation was identified by direct sequencing sequencing of the amplified cDNAs synthesized from of genomic polymerase chain reaction products in total RNA extracted from patients' lymphoblast cell each of four Finnish erythropoietic protoporphyria lines. Because the assays of the ferrochelatase a ctivity families. All four mutations, including two deletions and erythrocyte protoporphyrin identity asymptom­ (751deIGAGAA and the first de IIOVO mutation, atic patients poorly, the DNA-based d e monstration 1122deIT) and two point mutations (286C---') T and of a mutation is the only reliable way to screen 343C---') T), resulted in a dramatically decreased individuals for the dise ase-associated mutation. Key steady-state level of the allelic transcript, since none lVol'd: pOl'pl'Yl'ia. ] Invest Del'llwtol 106:346-350, 1996 of the mutations could he demonstrated by direct rythropoieti c pro toporphyria (EPP) is an inherited dis­ gene is 1269 bp in size, and only o ne isoform of the enzym e has ease caused by deficient activ ity of ferroch elatase been de m o nstrated (Nakahashi cl ai , 1990). T he gen e is at least 45 (hem e synthase; E.C.4.99.1.1), a mitoch o ndrial en­ kb in size and contains 11 ex ons (Take tani "I ai, 1992).
    [Show full text]
  • The Little Imitator-Porphyria: a Neuropsychiatric Disorder
    Journal ofNeurology, Neurosurgery, and Psychiatry 1997;62:319-328 319 REVIEW J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.62.4.319 on 1 April 1997. Downloaded from The little imitator-porphyria: a neuropsychiatric disorder Helen L Crimlisk Abstract Porphyria is derived from the Greek word por- Three common subtypes of porphyria phuros meaning purple. Protoporphyrin IX is give rise to neuropsychiatric disorders; the biologically active substance, an important acute intermittent porphyria, variegate feature of which is its metal binding capacity. porphyria, and coproporphyria. The sec- Both chlorophyll and haem are metallopor- ond two also give rise to cutaneous symp- phyrins and are involved in the processes of toms. Neurological or psychiatric energy capture and utilisation in animals and symptoms occur in most acute attacks, plants. The description of the porphyrins by and may mimc many other disorders. Nobel laureate Hans Fischer' in 1930 as: The diagnosis may be missed because it is "The compounds which make grass green not even considered or because of techni- and blood red." cal problems, such as sample collection indicates the central position of these sub- and storage, and interpretation of results. stances in the biological sciences. A negative screening test does not exclude The porphyrias are a heterogeneous group the diagnosis. Porphyria may be overrep- of overproduction diseases, resulting from resented in psychiatric populations, but genetically determined, partial deficiencies in the lack of control groups makes this haem biosynthetic enzymes. Their manifesta- Department of uncertain. The management of patients tions are broad and their relevance in neu- Neuropsychiatry, with porphyria and psychiatric symptoms ropsychiatric disorders may sometimes be Institute ofNeurology, causes considerable Queen Square, problems.
    [Show full text]
  • Porphyrin Metabolism and Haem Biosynthesis in Gilbert's Syndrome
    Gut: first published as 10.1136/gut.28.2.125 on 1 February 1987. Downloaded from Gut, 1987, 28, 125-130 Porphyrin metabolism and haem biosynthesis in Gilbert's syndrome K E L McCOLL, G G THOMPSON, E EL OMAR, M R MOORE, AND A GOLDBERG From the University Dept. Medicine, Gardiner Institute, Western Infirmary, Glasgow SUMMARY Studies in 14 patients with unconjugated hyperbilirubinaemia caused by Gilbert's syndrome have revealed abnormalities of the enzymes of haem biosynthesis measured in peripheral blood cells. The activity of the penultimate enzyme of haem biosynthesis protopor- phyrinogen (PROTO) oxidase was reduced at 3-1±2.6 nmol PROTO/g protein/h (mean±ISD) compared with 8*2±5-1 in controls (p<0.005). This was associated with a compensatory increase in the activity of the initial and rate controlling enzyme of the pathway delta-aminolaevulinic acid (ALA) synthase at 866±636 nmol ALA/g/protein/h compared with 156±63 in controls (p<0.001). Unlike variegate porphyria in which there is a genetic deficiency of PROTO oxidase there was no increased excretion of porphyrins or their precursors in Gilbert's syndrome. Accentuation and subsequent correction of the unconjugated hyperbilirubinaemia with rifampicin produced reciprocal changes in PROTO oxidase activity indicating that bilirubin may be inhibiting the activity of this enzyme. http://gut.bmj.com/ Gilbert's syndrome originally described in 1901 by ferase activity.`8 Gilbert's syndrome may be a Gilbert and Lereboullet' is a benign disorder affect- heterogenous disorder.9 We wish to report a pre- ing 2-5% of the population.
    [Show full text]
  • Congenital Erythropoietic Porphyria: Report of a Novel Mutation with Absence of Clinical Manifestations in a Homozygous Mutant Sibling
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Congenital Erythropoietic Porphyria: Report of a Novel Mutation with Absence of Clinical Manifestations in a Homozygous Mutant Sibling Ce´ cile Ged,à Hala Me´ garbane´ ,w Eliane Chouery,z Magalie Lalanne,à Andre´ Me´ garbane´ ,z and Hubert de Verneuilà ÃINSERM E 217, Universite´ Bordeaux2, Bordeaux, France; wServicedeDermatologie,HotelDieudeFrancedeBeyrouth,Beirut,Lebanon;zUnite´ de Ge´ ne´ tique Me´ dicale, Universite´ Saint-Joseph, Beirut, Lebanon In a Palestinian family, four siblings were shown to express typical and severe congenital erythropoietic porphyria (CEP). A new mutation of the uroporphyrinogen III synthase (UROS) gene was evidenced by systematic sequencing of the UROS gene: the substitution of serine by proline at the amino acid residue 47 (S47P) was present at the homozygous state in the four patients. The mother was heterozygous, the father was not examined. Surprisingly, in one unaffected sister, UROS activity was markedly deficient and UROS gene analysis showed a homozygous mutant profile. The deleterious role of the mutant S47P protein on UROS activity was demonstrated by prokaryotic expression. This observation is the first report of a healthy status associated with homozygosity for a mutation of UROS gene in a severely affected family. We then draw hypotheses to explain the protective phenotype in the homozygous healthy subject. Keywords: CEP/uroporphyrinogen III synthase/porphyrins/DNA studies/incomplete penetrance J Invest Dermatol 123:589 –591, 2004 Case Report Prokaryotic expression of the mutant S47P UROS protein demonstrated clearly that the S47P mutation was The members of the kindred under consideration (Fig 1) a disease-causing mutation (Table III).
    [Show full text]
  • Porphyria (Cutaneous) Testing Algorithm*
    Porphyria (Cutaneous) Testing Algorithm* Symptom: Skin manifestations restricted to sun-exposed areas Possible cutaneous porphyria: ■ Porphyria cutanea tarda (PCT) Symptoms: ■ ■ Edema Erythropoietic protoporphyria (EPP) PPFE / Protoporphyrins, ■ a ■ Sun-induced erythema Variegate porphyria (VP) Fractionation, Whole Blood ■ Hereditary coproporphyria (HCP)b ■ Acute painful photodermatitis ■ Congenital erythropoietic porphyria (CEP) ■ Urticaria ■ X-linked dominant protoporphyria (XLDPP) Normal Increased zinc Increased free Increased free and Symptoms: protoporphyrin protoporphyrin zinc protoporphyrins ■ Blistering lesions or bullae (>40% zinc ■ Skin fragility protoporphyrin) ■ Scarring Excludes EPP Consider: ■ EPP ■ Hyper/hypopigmentation ■ Iron de ciency anemia ■ Family studies ■ Possible hypertrichosis If clinically indicated ■ Heavy metal may be warranted intoxication Suspicious of XLDPP ■ Anemia of chronic Excludes Normal PQNRU / Porphyrins, Quantitative, disease FECHZ / Ferrochelatase PCT and CEP Random, Urine (includes PBG) (FECH) Gene, Full Gene Analysis If clinically Increased coproporphyrin Increased uroporphyrin Increased uroporphyrin and indicated and/or PBG and uroporphyrin and coproporphyrin heptacarboxylporphyrin Mutation No mutation indentified found FQPPS / Porphyrins, Feces UPGC / Uroporphyrinogen III Synthase UPGD / Uroporphyrinogen Confirms EPP (Co-Synthase) (UPG III S), Erythrocytes Decarboxylase (UPG D), Whole Blood Increased Increased coproporphyrin III/I coproporphyrin Normal Decreased Normal Decreased Normal ratio
    [Show full text]
  • Clinical Chemistry Trainee Council Pearls of Laboratory Medicine
    Clinical Chemistry Trainee Council Pearls of Laboratory Medicine www.traineecouncil.org TITLE: Porphyrias PRESENTER: M. Laura Parnas Slide 1: Hello, my name is Dr. Laura Parnas. I am the Associate Medical Director of Laboratory Services at the Palo Alto Medical Foundation. Welcome to this discussion on porphyrias. The porphyrias are a group of rare inborn errors of metabolism associated with defects in the heme biosynthetic pathway. Enzymatic deficiencies during heme biosynthesis result in accumulation and excretion of pathway precursors and intermediates, causing unique biochemical features and disease symptoms. Slide 2: Heme Heme is a crucial component of cellular hemoproteins that fulfill essential functions, including oxygen transport and storage, electron transport, and oxidation-reduction reactions. Heme biosynthesis occurs in all nucleated cells in the human body, primarily in developing red blood cells of the bone marrow where hemoglobin is produced, and to a lesser extent in hepatocytes, where cytochromes and other heme-containing enzymes are generated. Slide 3: Heme Biosynthesis Heme is enzymatically produced in sequential steps that occur in two cellular compartments; the first and last three steps occur in the mitochondrion and the intermediate steps take place in the cytosol. Eight enzymes catalyze formation of protoporphyrin IX and iron chelation to form heme. The initial and rate-limiting step is the condensation of glycine and succinyl-CoA to form δ- aminolevulinic acid (ALA). Then, condensation and polymerization reactions occur to form hydroxymethylbilane. Cyclization of hydroxymethylbilane can occur spontaneously to generate type I isomers, but the enzymatically-generated type III isomers are most abundant and physiological. The last steps include decarboxylation, oxidation, and insertion of iron to complete the cycle.
    [Show full text]
  • Scientific Workshop on Erythropoietic Protoporphyria (EPP)
    Scientific Workshop on Erythropoietic Protoporphyria (EPP) October 24, 2016 www.fda.gov 1 Welcome October 24, 2016 www.fda.gov Agenda • Overview of EPP and Current Treatment Approaches • Patient Perspectives on EPP and Current Treatments • Open Public Comment LUNCH • Overview of FDA Regulatory Process • Scientific Discussion on Clinical Trial Design for EPP • Open Public Comment • Closing Remarks www.fda.gov 3 3 Opening Remarks Kendall Marcus, MD Director, Division of Dermatology and Dental Products (DDDP) Center for Drug Evaluation and Research U.S. Food and Drug Administration October 24, 2016 www.fda.gov Epidemiology and Natural History of Erythropoietic Protoporphyria Henry W. Lim, MD Chairman and C.S. Livingood Chair Department of Dermatology Henry Ford Hospital, Detroit, MI Disclosure • Consultant : • Investigator: – Pierre Fabre – Clinuvel – Estée Lauder – Ferndale Erythropoietic Protoporphyria • Onset in childhood • Burning, stinging sensation • Erythema, edema, urticarial lesions • Rare: late onset with myelodysplasia Heme Biosynthetic Pathway ALA Hydroxymethylbilane Uro-/ Coproporphyrinogen Protoporphyrin Ferrochelatase EPP Iron Heme X-linked Dominant Protoporphyria (XLDPP) (Schulenburg-Brand, D, … Badminton, MN. Dermatol Clinics 2014; 32:369. Cardiff, Wales) • Similar to EPP: burning, stinging, edema upon exposure to sunlight Prevalence of EPP (per 100,000) (Horner, ME, et al. Int J Dermatol. 2013 Dec;52:1464; Gouya L, et al. Am J Hum Genet 2006 Jan; 78:2.) Country Per 100,000 Japan 4.00 Slovenia 1.75 United Kingdom 0.77 North Ireland 1.27 Netherlands 1.33 South Africa General 0.06 population European 0.70 immigrant population EPP in the UK (Holme SA,… Badminton, MN. Br J Dermatol 10/2006; 155:574. Cardiff) • 389 living subjects identified • 223 (114 f, 109 m) investigated • Median age: 34 yrs (5-87 yrs) • Median total erythrocyte porphyrin: – Males: 25.3 micromole/l – Females: 19.3 micromole/l EPP in the UK (Holme SA,… Badminton, MN.
    [Show full text]